Vancouver, BC, Canada – Boreal Genomics, the developer of the SCODA nucleic acid purification and sequence specific target enrichment technology, announced today that Nitin Sood has been appointed Chief Executive Officer and member of the company’s Board of Directors.

Sood joins founder and Chief Scientific Officer, Dr. Andre Marziali, who will continue serving as a Board member and on the company Executive Team. Sood joins Boreal from Agilent Technologies, Life Science Group, where he most recently served as General Manager in charge of the Automation business. In his 5 years at Agilent, he led the growth of business units in both Automation (Santa Clara, CA) and Electrophoresis (Waldbronn, Germany) demonstrating successful launch of new

products, increases in revenue and profitability, and development of emerging markets.

Sood brings more than 15 years of experience in product development and commercialization, which includes senior management experience at Applied Biosystems. Sood holds master’s degrees in computer science and molecular biology.

“We are delighted to have Nitin join the Boreal team as our new CEO. As Boreal has grown beyond the research stage to product commercialization and distribution, we feel fortunate to have attracted someone of Nitin’s caliber to drive Boreal toward commercial success. Nitin’s outstanding successes at Agilent, his proven leadership skills, and extensive experience in instrument commercialization will power the next stages of growth at Boreal as we move toward new markets in forensics and clinical diagnostics,” said Marziali.

We are very excited about the innovation and application progress Boreal has made to date. Coupling this remarkable progress and the Boreal team with first tier commercial leadership in the person of Nitin Sood, is a powerful combination and one that will lead Boreal to important commercial successes,” said Keith Crandell, Co?founder and Managing Director, ARCH Venture Partners.

About Boreal Genomics

Boreal Genomics is committed to the development and commercialization of high performance methods and instruments for nucleic acid purification, enrichment, and detection. Boreal Genomics was founded by leading researchers in the field of nucleic acid analysis methods from the University of British Columbia. An extensive patent portfolio is being prosecuted to give broad IP protection to the Boreal technology. These patents have been exclusively licensed from UBC to Boreal for commercialization.

Boreal’s Synchronous Coefficient of Drag Alteration (SCODA) is a proprietary and novel nucleic acid concentration and extraction technology that excels in applications where other techniques fail by offering unique advantages including: exceptional contaminant rejection, an unparalleled ability to enrich low abundance nucleic acids, and ability to enrich for specific nucleic acid sequences. Recently developed methods allow Boreal to enrich for single nucleotide mutations by at least 10,000 fold over wild type sequence, offering unique opportunities in oncology and infectious disease applications for detection of rare sequences.

Boreal aims to leverage these advantages to provide uniquely powerful DNA extraction technology to customers in life science research, forensics, and clinical diagnostics. With close connections to UBC, Genome BC, as well as a strong network within the San Francisco Bay Area, Boreal has built a top?notch team, composed of outstanding young recruits, mixed with seasoned entrepreneurs and advisors. Boreal prototype instruments have been field tested, demonstrating success at DNA extraction from previously intractable sample types ranging from tar sands to forensic samples.